This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

HCG in testicular cancer

Authoring team

Human chorionic gonadotrophin (HCG)

  • HCG is normally synthesised in syncytiotrophoblasts of the placenta, and is also produced in malignancy, in trophoblastic structures or syncytiotrophoblastic giant cells of germ cell tumours (1,2). Some non-trophoblastic tumours synthesise hCG.
  • very high serum HCG concentrations occur in hydatidiform moles ("molar" pregnancies) and choriocarcinomas (97%)
  • serum HCG levels may be increased in pancreatic adenocarcinomas and islet cell tumours, tumours of the small and large bowel, hepatoma, stomach, lung, ovarian, breast and renal cancer
  • for tumour marker use, measurement of both intact HCG and its free beta subunit (betaHCG) is highly desirable, as some tumours may produce only betaHCG
  • increased serum HCG concentrations occur in both seminoma and non-seminomous germ cell tumours (NSGCT), with a diagnostic sensitivity of 40-60% in patients with metastatic NSGCT and 15-20% in those with metastatic seminoma. HCG elevations are predominantly found in patients with tumours containing choriocarcinomatous components, syncytiotrophoblastic giant cells and (more rarely) special round cells also found in pure seminomas.

Reference:

  1. Mann K: Tumor markers in testicular cancers. Urologe A 29: 77-86, 1990.
  2. Doherty AP, Bower M, Christmas TJ: The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers. Br J Urol 79: 247-252, 1997

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.